Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Monday session in red amid volatile trading. The shares closed down -0.46 points or -1.03% at $44.41 with 4.60 million shares getting traded. Post opening the session at $44.18, the shares hit an intraday low of $44.14 and an intraday high of $44.45 and the price vacillated in this range throughout the day. The company has a market cap of $106.63 billion and the numbers of outstanding shares have been calculated to be 4.87 billion shares.
GlaxoSmithKline plc (ADR) (GSK) on July 20, 2016 announced it has begun shipping quadrivalent vaccine doses to US healthcare providers, following licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research. It is the first company to ship quadrivalent vaccine for the 2016-17 flu season.
The US Centers for Disease Control and Prevention (CDC) recommends flu vaccination as the single best measure for flu prevention. The CDC has a routine recommendation for Americans over the age of six months to get a flu vaccination each year as the first and most important step in protecting against this disease. GSK’s flu vaccines are indicated for use in persons three years and older.
“Our goal is to be a reliable partner in the annual flu immunization campaign by developing and manufacturing high quality quadrivalent influenza vaccines for the US population,” said Patrick Desbiens, Senior Vice President, US Vaccines. “This year we introduced new functionality to our eCommerce platform, www.GSKDirect.com, to allow those who stock and administer our vaccines to further accelerate delivery of their flu vaccines when they order directly from us. We believe this enhancement supports healthcare providers by helping to ensure that their patients have access to the vaccines they need.”
Shares of Opko Health Inc. (NYSE:OPK) closed at $10.11 with 4.72 million shares getting traded. Post opening the session at $10.19, the shares hit an intraday low of $10.05 and an intraday high of $10.22 and the price vacillated in this range throughout the day. The company has a market cap of $5.61 billion and the numbers of outstanding shares have been calculated to be 547.44 million shares.
Opko Health Inc. (OPK) on August 9, 2016 reports financial and operating results for the three and six months ended June 30, 2016.
Financial Highlights
- Consolidated revenues for the three months ended June 30, 2016 increased to $357.1 million from $42.4 million for the three months ended June 30, 2015. The 2016 period includes revenue from BioReference Laboratories and EirGen which were acquired in August and May 2015, respectively. In addition, the 2016 period includes $50.0 million of revenue related to our license of RAYALDEE to VFMCRP.
- Net income for the three months ended June 30, 2016 was $15.5 million compared with net loss of $42.8 million for the 2015 period. Net income (loss) during the three month periods include significant non-recurring and non-cash activities, including:
- Upfront payment for the license of RAYALDEE to VFMCRP of $50.0 million; and
- Other income and (expense) was $5.1 million and ($16.8) million in the 2016 and 2015 periods, respectively, primarily related to the change in fair value of derivative instruments. The change in fair value is principally related to an embedded derivative in OPKO’s January 2013 convertible senior notes due in 2033.
- Upfront payment for the license of RAYALDEE to VFMCRP of $50.0 million; and
- Other income and (expense) was $5.1 million and ($16.8) million in the 2016 and 2015 periods, respectively, primarily related to the change in fair value of derivative instruments. The change in fair value is principally related to an embedded derivative in OPKO’s January 2013 convertible senior notes due in 2033.
- Cash, cash equivalents and marketable securities were $171.6 million as of June 30, 2016.